Health Food Symmetry offers a standout way to capitalise on the growing gut health market. Backed by world-first, clinically validated prebiotic technology, a $10M GMP-certified facility, and established retail and B2B traction, HFS is positioned to deliver scalable growth ahead of its planned ASX listing.
Health Food Symmetry Limited
HFS
Lead Manager
Contact - Jake Grbavac
0474 484 982
jake@liquidity.com.au
Minimum Investment
A$2,000
Offer Details
Issue Price (Per Share)
A$0.400
Offer Size
A$2,000,000
Shares Available
5,000,000
The Company is offering up to 5,000,000 shares at an issue price of $0.40 per share to raise up to $2,000,000.
Minimum Subscription: $200,000
Maximum Subscription: $2,000,000
Documents & Downloads
Company Overview
Health Food Symmetry (HFS) is an Australian company that has carved out a unique position in gut health by turning sugarcane fibre, traditionally discarded, into clinically validated prebiotic solutions. Through its breakthrough process that preserves the natural fibre matrix and phytonutrients while removing sugar, HFS created PhytoBiome, a next-generation prebiotic with proven benefits for digestive comfort, microbiome balance, and long-term gut health. Its research partnerships with RMIT, the University of Tasmania, and the University of Queensland have underpinned the credibility of its science, with applications now spanning dietetics, hospital care, elite sports, and even veterinary health.
From its GMP-certified, FDA-registered facility in Queensland, HFS manufactures at scale for human supplements, food and beverage innovation, and animal health, with products including Phytocel, PhyteQuine, and Kfibre. The company also supports global health brands through white-label partnerships, expanding the reach of its platform.
The Problem
Digestive disorders are a major global health issue, affecting over 4.6 billion people and ranking among the most common chronic conditions worldwide. Conditions like IBS, Acid Reflux, IBD, and FGIDs significantly impact quality of life and productivity. In Australia, ~50% of adults experience digestive issues annually, and globally ~40% of people live with FGIDs.
Current solutions are limited:
- Pharmaceuticals provide symptom relief but carry long-term side effects and don’t address microbiome dysfunction.
- Common fibre supplements (psyllium, inulin, wheat dextrin) often cause bloating and discomfort, resulting in poor adherence.
- Digestive issues also affect animals, with performance horses and pets commonly impacted; yet most available solutions are generic or synthetic, with limited long-term efficacy.
The Opportunity - Market Overview
Segment
Current Value
Projected Value
Timeline
Key Drivers
Gut Health
~$51–52B (2023–24 est.)
$270B
2034
Demand for natural, clinically supported, diet-friendly products (low-FODMAP, gluten-free, plant-based). Current products lack consistent efficacy.
Prebiotics (sub-segment)
~$6.7–7.6B (2023–24 est.)
$10.5B
2030
Strong growth within gut health; market more than doubling.
Weight Loss Supplements
$24.6–28.7B (2023)
$77–100B
2032–33
Rising obesity rates, growing health consciousness.
Anti-Inflammatory Biologics
$104.8B (2024)
$148.08B
2030
Rising prevalence of psoriasis, rheumatoid arthritis, IBD, and other autoimmune diseases.
Gluten-Free Products
$7.7B (2024)
$12.7B
2034
Demand for gluten-free diets and alternatives.
Allergen-Free Foods
$50.37B (2025)
$102.84B
2035
CAGR 7.4%, rising food allergies, demand for healthier and safer food options.
HFS's Solution
HFS's flagship product, PhytoBiome, is the worlds first sugarcane-derived, whole plant-based prebiotic.
Backed by over a decade of research, protected by intellectual property, and supported by clinical validation, PhytoBiome addresses the shortcomings of isolated fibre products that dominate the market. Its unique composition ensures high tolerability, sustained efficacy, and broad application across human, animal, and food markets.
With a foundation of innovation, clinical credibility, and scalable GMP/FDA-registered production, HFS is uniquely placed to capture significant value across multiple sectors in a rapidly expanding global market.
Key Products
PhytoBiome
- The world’s first sugarcane-derived, whole-plant prebiotic, produced through a patented, chemical-free process that retains fibre and phytonutrients while removing sugar.
- Backed by clinical validation, Low-FODMAP certification, FSANZ health claims, and TGA listings (#83538, #96540).
- Delivers balanced fermentation, microbiome diversity, and digestive comfort, trusted by clinicians and researchers
Phytocel
- An application-ready ingredient that enhances product performance with natural moisture retention, extended shelf life, and improved yields in baked goods and snacks.
- Supports food brands in delivering “better for you” products while meeting regulatory compliance.
- Combines functional benefits with proven prebiotic nutrition, creating value for both industry and consumers.
PhyteQuine
- Supports gut health in performance, working, and companion horses by stabilising digestion and improving nutrient absorption, offering a natural alternative to synthetic additives.
- With 20%+ of equine supplement sales tied to digestive health, it is well-positioned for strong market adoption.
- A pelletised format in development will make supplementation more convenient for owners and trainers.
Kfibre
- A consumer brand delivering PhytoBiome’s benefits in a convenient powder that supports digestion, microbiome balance, and overall wellbeing.
- Low-FODMAP, non-GMO, and gluten-free, it is widely recommended by dietitians and used in clinical practice.
- Builds retail awareness of HFS innovation, anchoring the company’s broader product platform.
Revenue Model
Core Revenue Streams
Ingredient Sales (B2B):
- PhytoBiome – premium, clinically validated prebiotic for nutraceutical and healthcare markets.
- Incorporated into consumer products from brands such as Healthyroo, Fertile Gut, Chief Nutrition, Real Good Food, and True Foods
- International expansion underway, with Healthyroo entering the Middle East and planning launches in India and Asia.
- Phytocel – functional ingredient for food and beverage manufacturers, enhancing both nutrition and formulation.
Retail & Consumer Products (B2C):
- Kfibre – consumer brand sold through health retailers, pharmacies, and e-commerce.
- Trialled and adopted by major hospitals, including WA Health, NSW Health, and the Royal Women’s Hospital.
- Distributed through 425 stores and five distributors via Sunrise Health & Wellness Pty Ltd
- White-label and co-branded ranges under development.
Animal Health (B2B & B2C):
- PhyteQuine – equine digestive health product supplied via veterinary networks and retail.
- Companion animal applications (PhytoCanis ) in expansion.
Use of Funds
Minimum Subscription
Maximum Subscription
A$
%
A$
%
Upgrades to Manufacturing Plant
$0.00
%
$450,000.00
22.5%
Acquisition & Installation of Decanter Centrifuge
$0.00
%
$350,000.00
17.5%
Pellitisation Machinery
$0.00
%
$110,000.00
5.5%
New Product Development
$0.00
%
$90,000.00
4.5%
Manufacture Stock of Finished Product
$0.00
%
$300,000.00
15%
Expansion of Sales
$50,000.00
25%
$240,000.00
12%
Working Capital
$150,000.00
75%
$460,000.00
23%
Upgrades to Manufacturing Plant
(Min Subscription)
(Max Subscription)
$0.00
$450,000.00
%
22.5%
Acquisition & Installation of Decanter Centrifuge
(Min Subscription)
(Max Subscription)
$0.00
$350,000.00
%
17.5%
Pellitisation Machinery
(Min Subscription)
(Max Subscription)
$0.00
$110,000.00
%
5.5%
New Product Development
(Min Subscription)
(Max Subscription)
$0.00
$90,000.00
%
4.5%
Manufacture Stock of Finished Product
(Min Subscription)
(Max Subscription)
$0.00
$300,000.00
%
15%
Expansion of Sales
(Min Subscription)
(Max Subscription)
$50,000.00
$240,000.00
25%
12%
Working Capital
(Min Subscription)
(Max Subscription)
$150,000.00
$460,000.00
75%
23%
Board & Management
Gordon Edwards
Managing Director & Chief Executive Officer
Mr Edwards is responsible for the overall Company direction utilising his background in small medium enterprise (SME) start-ups, fund raising and product development. He is a founding shareholder in HFS and the CEO. Gordon spent a number of years in building and operating food related businesses. During this period, he formally qualified as an engineer.
David McBain
Director
Extensive experience in business consulting, governance, taxation, business assurance and provision of CFO and Corporate Secretarial services to listed and other entities including IPO experience.
Richard Revelins
Chairman
Mr Revelins is a Director and co-founder of Peregrine Corporate Limited and also a Managing Director at Cappello Group Inc in Los Angeles, USA. Mr Revelins has over 35 years of expereince with international investment banks in the area of corporate finance and corporate advice. He has predominantly specialised in mining and natural resources and was the former Chairman of Atlas Iron Ltd as well as a director of numerous other public and private companies. He was appointed as a director and CEO of Meryllion Resources Corporation on 1 March 2022. MYR is listed on the CSE. Mr Revelins is a founding director and shareholder in HFS.
Disclaimer
This site does not constitute an offer, recommendation, or invitation to any person, nor does it purport to provide all of the information an interested party may require in order to investigate the affairs of Health Food Symmetry Limited. This site is provided for information only and has not been prepared with the intention that the recipient should rely on it. Liquidity Technology Pty Ltd ("Liquidity") does not make any representation in relation to the contents of this site or give any assurances as to the accuracy or the degree of care or diligence used in preparing this document. The information, data, and advice herein is provided to recipients on the clear understanding that Liquidity nor any of its representatives, directors, officers, employees, agents, or advisers makes any representation or warranty about its accuracy, reliability, completeness, or suitability for any particular purpose and does not accept liability (including, but not limited to, for any expenses, losses, damages, and/or costs (including, but not limited to, indirect or consequential damage)) nor take any responsibility of any kind whatsoever (including, but not limited to, whether in contract, tort, financial or otherwise) for the information, data, or advice contained in or for any omission or for any other information, statement, or representation provided to any recipient (including, but not limited to, as a result of information, data, or advice being inaccurate, unreliable, incomplete, or unsuitable in any way and for any reason whatsoever). Users of this site must conduct their own investigation and analysis regarding any information, statement, or representation contained or provided to any recipient or its associates by Liquidity or any of the Liquidity Personnel. Each recipient waives any right of action, which it has now or in the future against Liquidity or any of the Liquidity Personnel in respect of any errors or omissions on or from this site, however caused. All rights are reserved. If the whole or any part of a provision of this "Notice and Disclaimer" is invalid, illegal, or unenforceable, then such provision will be severed and neither that part or provision or its severance will affect the validity or enforceability of the remaining parts or provisions.
Disclosure of Interest: Liquidity receives commission from dealing in securities and its introducers of business may directly share in this commission. Liquidity and its associates may hold shares in Health Food Symmetry Limited.
